Kirkland

Researchers are evaluating a method to improve early detection of ovarian and endometrial cancers in women aged 45 years and older who have symptoms like bloating, abdominal or pelvic pain, increased urinary frequency, or early fullness after eating. The study aims to see if earlier surgery guided by screening tests can benefit these women by diagnosing cancer at an early, curable stage. Participants undergo a CA-125 blood test and a transvaginal ultrasound at the start of the study, with a second CA-125 blood test six weeks later. A follow-up phone call occurs six months after the last visit to check on participants' health. During the study, researchers track the proportion of participants diagnosed with early-stage cancer over up to three years. The study involves symptom monitoring, blood biomarker testing, ultrasound imaging, and health status verification through phone follow-up to assess the effectiveness of early detection strategies.

Researchers are evaluating the safety and effectiveness of pembrolizumab (MK-3475) combined with various therapies in men with metastatic castration-resistant prostate cancer (mCRPC). This Phase Ib/II trial includes ten different groups receiving different combination treatments, such as pembrolizumab with olaparib, docetaxel plus prednisone, enzalutamide, abiraterone plus prednisone, lenvatinib, vibostolimab coformulation, carboplatin plus etoposide, and belzutifan. The study aims to assess each group's outcomes separately, focusing on prostate-specific antigen (PSA) reduction, tumor response, and safety over about two years. Participants receive treatments according to their assigned group, with pembrolizumab given intravenously every three weeks along with other drugs taken orally or intravenously based on the combination. Some groups have closed enrollment following protocol amendments, and participants who stop treatment under specific conditions may be eligible for a second course of pembrolizumab or pembrolizumab/vibostolimab for up to one year if their cancer progresses. Treatments include chemotherapy agents, hormonal therapies, targeted drugs, and immunotherapies. During the study, participants will be monitored every three weeks for PSA levels, tumor response using imaging reviewed by independent experts, and any side effects. Other assessments include tissue biopsies and evaluations of overall health and function. The study lasts about two years, with ongoing safety and effectiveness monitoring, including follow-up for adverse events and treatment discontinuations due to side effects.